Drugs / EDP-721
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04971512 | Aug → Dec 2021 | chronic hepatitis B virus infection | Enanta Pharmaceuticals, Inc | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-11-18 | Enanta Pharmaceuticals, Inc | Results Enanta Pharmaceuticals Announces Update to its Hepatitis B Virus (HBV) Program enanta.com ↗
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced it is discontinuing development of EDP-721, an oral HBV RNA destabilizer, based on emerging safety observations in the single ascending dose part of a Phase 1 study in healthy volunteers. |
| 2021-06-23 | Enanta Pharmaceuticals, Inc | Results Enanta Pharmaceuticals Presents New Data for EDP-721, an Oral Hepatitis B Virus RNA Destabilizer, at the European Association for the Study of the Liver (EASL) International Liver Congress™ enanta.com ↗
The data demonstrate potent, selective and pangenotypic inhibition of HBV surface antigen (HBsAg), with up to a 3-log drop in the AAV-HBV mouse model. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-11-18 | Enanta Pharmaceuticals, Inc | Enanta Pharmaceuticals Announces Update to its Hepatitis B Virus (HBV) Program enanta.com ↗ |
| 2021-08-16 | Enanta Pharmaceuticals, Inc | Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA Destabilizer enanta.com ↗ |
| 2021-06-23 | Enanta Pharmaceuticals, Inc | Enanta Pharmaceuticals Presents New Data for EDP-721, an Oral Hepatitis B Virus RNA Destabilizer, at the European Association for the Study of the Liver (EASL) International Liver Congress™ enanta.com ↗ |
| 2021-06-03 | Enanta Pharmaceuticals, Inc | Enanta Pharmaceuticals to Present Preclinical Data for EDP-721, its Novel Oral Hepatitis B Virus RNA Destabilizer, at the International Liver Congress™ 2021 Sponsored by the European Association for the Study of the Liver enanta.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EDP-721 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04971512 ↗ |
| Route | Oral | “Oral administration (Part 1)” NCT04971512 ↗ |